Autism is a neurodevelopmental disorder whose diagnosis is based on three behavioral criteria: unusual reciprocal social interactions, deficits in communication, and stereotyped repetitive behaviors with restricted interests. A large number of de novo single gene mutations and chromosomal deletions are associated with autism spectrum disorders. Based on the strong genetic evidence, mice with targeted mutations in homologous genes have been generated as translational research tools. Mouse models of autism have revealed behavioral and biological outcomes of mutations in risk genes. The field is now poised to employ the most robust phenotypes in the most replicable mouse models for preclinical screening of novel therapeutics.

Keywords: neurodevelopmental disorder; autism; genetics; mouse model; social behavior; therapeutics; olfactory; ultrasonic vocalization; repetitive behavior; self-grooming; anxiety; cognitive; fragile X; tuberous sclerosis; mGluR5 antagonist

Author affiliations: Robert Chason Chair in Translational Research, M.I.N.D. Institute Professor of Psychiatry and Behavioral Sciences, School of Medicine, University of California, Davis, Sacramento, California, USA

Address for correspondence: Jacqueline N. Crawley, PhD, Robert Chason Chair in Translational Research, M.I.N.D. Institute, Professor of Psychiatry and Behavioral Sciences, School of Medicine, University of California, Davis, Research II Room 1001A, Sacramento, CA 95817 USA (e-mail: crawley@ucdavis.edu)
models of autism. In addition, recent advances in generating knockout rats are leading to the development of mutant rat models of neurodevelopmental disorders.

Because concordance for autism spectrum disorder is not 100% between identical twins, whose genomes are presumably identical, environmental and epigenetic causes of autism spectrum disorders are also under investigation. Hypotheses about prenatal exposure to toxicological and immunological insults, and neuroanatomical lesions, have been modeled in mice, rats, and monkeys. The challenge now is to understand the consequences of each of these genetic and environmental perturbations, and their interactions. Animal models employing behavioral assays relevant to the specific symptoms offer excellent translational research tools to identify the biological mechanisms underlying the core features of autism spectrum disorder.

### How do we model the behavioral symptoms of autism in mice?

As defined in the *DSM-IV*, the diagnosis of autism requires the presence of at least six symptoms, including a minimum of two measures of qualitative impairment in social interaction, one symptom of qualitative impairment in communication, and one symptom of restricted and repetitive behaviour. The *DSM-5* is expected to redefine Autism Spectrum Disorder into two symptom domains: (i) Social interaction and social communication deficits; (ii) Restricted, repetitive patterns of behavior, interests, or activities (http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=94, January 2011). Associated symptoms that appear in subsets of individuals with autism include seizures, anxiety, intellectual impairment, hyperactivity, hyper-reactivity and hyporesponsiveness to sen-

| Gene       | Protein                  | Autism-relevant behavioral phenotypes                                                                 |
|------------|--------------------------|-------------------------------------------------------------------------------------------------------|
| Integrin β3| Integrin β3              | Lack of preference for social novelty                                                                 |
|            |                          | Increased repetitive self-grooming                                                                  |
| Nlgn1      | Neuroligin 1             | Increased repetitive self-grooming                                                                  |
| Nlgn2      | Neuroligin 2             | Increased anxiety-like behavior                                                                    |
| Synaptic  | Nlgn3                    | Reduced pup ultrasonic vocalizations                                                                |
| cell-adhesion proteins | Neuroligin 3          | Sensory abnormalities                                                                                 |
| Ngin4      | Neuroligin 4             | Reduced sociability and vocalizations                                                              |
| Neurexin-1α| Neurexin-1α              | Increased repetitive self-grooming                                                                  |
| Cnmap2     | Contactin-associated protein2 | Seizures, reduced social behaviors                                                                      |
| Shank3     | Shank3                   | Mild reduction in social interactions and adult vocalizations                                         |
| En2        | Engrailed-2              | Reduced social behaviors - Impaired learning and memory                                              |
| Met        | Tyrosine kinase/ hepatocyte growth factor receptor | Cognitive deficit                                                                                 |
| proteins   | Foxp2                    | Reduced pup ultrasonic vocalizations                                                              |
|            | Pten                     | Reduced reciprocal social interactions - Reduced sociability                                           |
|            |                          |                                                                                                      |
| Aurop1     | Vasopressin receptor     | Impaired social recognition - Reduced reciprocal social interaction                                 |
| Neurotransmitters | Cadps2             | Reduced reciprocal social interactions                                                              |
| and receptors | Gabrb3              | Low sociability - Lack of preference for social novelty                                              |
| Oxtr       | Oxytocin receptor        | Impaired social recognition - Reduced pup ultrasonic vocalizations                                 |
| Slc6a4     | Solute carrier family 6, member 4 (Serotonin transporter) | Low sociability - Lack of preference for social novelty                                                |

Table I. Autism-relevant behavioral phenotypes in selected mouse models with targeted mutations in genes associated with autism.
sory stimuli, sleep disruption, and gastrointestinal distress. 

Given that the defining criteria for autism are behavioral, investigations employing mouse models require considerable insight into which specific behaviors in the mouse repertoire are sufficiently relevant to each category of the diagnostic symptoms of autism. Inclusion of behavioral assays relevant to associated symptoms further enhance the heuristic value of animal models of autism spectrum disorders. We and other behavioral neuroscientists have generated a comprehensive set of assays for social interaction, social communication, and repetitive behaviors in mice, to test hypotheses about the causes of autism. 

Social approach, reciprocal social interactions, olfactory communication, ultrasonic vocalizations, motor stereotypes such as circling and vertical jumping, repetitive behaviors such as self-grooming and digging, and perseveration in spatial tasks, are now in routine use for phenotyping mouse and rat models of autism and other neurodevelopmental disorders.

Procedures for assaying behaviors relevant to associated symptoms of autism, including neurodevelopmental milestones, cognitive abilities, anxiety-like tendencies, seizures, motor dysfunctions, hyperactivity, responsiveness to sensory stimuli, and altered sleep patterns in mice have been adapted from the available behavioral neuroscience literature.

In each case, we begin with the human endophenotype. In what ways are mouse behaviors similar to a defining feature of autism? Luckily, Mus musculus is a social species. Laboratory mice display a social repertoire that includes approach to olfactory pheromones emitted by other mice, approach to familiar and new conspecifics, reciprocal social interactions, ultrasonic vocalizations, communal nesting, sexual and parenting behaviors, territorial scent marking, and aggressive behaviors.

Standardized methods for scoring adult social approaches, reciprocal social interactions, nesting, sexual interactions, parental behaviors, and aggressive encounters are available in the behavioral neuroscience literature.

First diagnostic category

We employ social assays that have been refined from standard tests in the behavioral neuroscience literature. These choices are designed to maximize relevance to the types of social deficits specific to autism, including playing alone with inanimate toys rather than engaging in social interactions, and inappropriate responses to social cues. To quantify tendencies to engage in reciprocal social interactions, each subject mouse is paired with a novel partner mouse, inside a testing arena that permits free interactions over a test session of 10 to 30 minutes’ duration. Digital video cameras record the session for later scoring of multiple parameters of social interactions. Ratings are performed by investigators who are blind to the genotype or treatment of the subject mice. Parameters routinely scored include sniffing, following, physical contact, and allogrooming.

Automated videotracking systems can accurately score some of the simpler elements of social interactions.

Tendency to spend time with a novel mouse versus a novel nonsocial object is evaluated in a social approach apparatus (Figure 1). This 3-chambered assay, which was developed by our team to provide a simple measure of general sociability, is widely used as an initial, high-throughput test for social deficits in mouse models of autism.

Second diagnostic category

Social communication in rodents is mostly through the emission and detection of olfactory pheromones, and perhaps to a lesser extent, the emission and detection of ultrasonic vocalizations. Olfactory communication is assayed by time spent sniffing olfactory stimuli from novel mice, and identification of novel versus familiar mice through olfactory cues.

Vocal communication is assayed by recording ultrasonic vocalizations emitted during social interactions (Figure 2). Number of calls and their properties are subsequently scored by investigators. Software is available for quantifying some of the simpler parameters. Different patterns of ultrasonic vocalizations are emitted by separated pups, adult males interacting with estrus females or urine from estrus females, adult females interacting with each other, and adult male residents in response to an intruder.

The anatomical and neurobiological substrates of olfactory and ultrasonic communication in mice do not precisely map onto the biological substrates of language and visual social communication in humans. In addition, considerably more work is needed to fully understand the communication value of ultrasonic vocalizations in mice.
At present, the existing tasks offer a reasonable start for discovering mechanistic similarities between species. Face validity of these mouse social interaction and communication tasks to the tendencies of people with autism to engage in less social approach and interaction, and to respond appropriately to complex social cues, remains inferential. We cannot know what a mouse is thinking, feeling, or intending, but only the quantifiable external expressions of those internal states.

Third diagnostic category

Mice with various genetic mutations exhibit spontaneous motor stereotypies such as circling and vertical jumping, and spontaneous repetitive behaviors such as long bouts of self-grooming and excessive digging in the litter (Figure 3). Assays generally focus on the number of bouts of the behavior, or the cumulative time engaged in the behavior, during a defined test session of 10 minutes or

Figure 1. (a) Social approach apparatus for assaying sociability in mice. The subject mouse begins in the empty center chamber of a three-chambered Plexiglas apparatus. A novel object, an inverted wire pencil cup, is placed in one side chamber. A novel mouse, who has not been in visual, olfactory, or tactile contact with the subject, is placed inside an identical wire control cup in the opposite side chamber. Over a 10-minute test session, the automated photocells and software score the amount of time the subject mouse spends in each of the three chambers. The number of entries into each compartment is simultaneously recorded as an internal control for general exploratory activity. Time spent engaged in bone fide social interactions with the novel mouse, and directed exploration of the novel object, are subsequently scored from digital videotapes of the session, by investigators uninformed of the genotype or treatment condition. Photograph by Dr Mu Yang, contributed by the author.

(b) Social approach chamber time scores in adult Engrailed2 (En2) knockout mice. Normal sociability is defined as more time spent in the chamber with the novel mouse than in the chamber with the novel object, and more time spent sniffing the novel mouse than sniffing the novel object. Wild-type littermate controls and heterozygotes displayed normal sociability on the chamber time parameter, while En2 null mutants failed to display sociability on this parameter. Reproduced from reference 170: Briemraier J, Matteson PG, Silverman JL, et al. Autism-relevant social abnormalities and cognitive deficits in engrailed-2 knockout mice. PLoS One. 2012;7:e40914.

(c) Social approach sniff time scores in adult En2 mice. Wild-type littermate controls and heterozygotes displayed normal sociability on the sniff time parameter, while En2 null mutants failed to display sociability on this parameter. Time spent sniffing the novel mouse is a more direct measure of social interactions, and usually more sensitive to mutations. Reproduced from reference 170: Briemraier J, Matteson PG, Silverman JL, et al. Autism-relevant social abnormalities and cognitive deficits in engrailed-2 knockout mice. PLoS One. 2012;7:e40914.
longer. Restricted interests, insistence on sameness, and special interests are more challenging diagnostic features of autism to model in mice. Perseveration of spatial habits, such as difficulty in learning a new location of a reinforcer in a T-maze or water maze after the initial learning of a first location, has been employed with some success in mouse models of autism. 40,58,65,79-81

**Associated symptoms**

Established, standardized tests are available in the voluminous behavioral neuroscience literature for most of the associated symptoms of autism. 40,54-60 Neurodevelopmental milestones are scored from postnatal day 2 to postnatal day 18 on physical attributes such as body length and eye opening, and behavioral attributes such as responses to handling and the righting reflex. Spontaneous seizures are scored with a rating scale or EEG electroencephalography. Learning and memory tests for mice include Morris water maze spatial navigation tasks, contextual and cued fear-conditioned freezing after exposure to an aversive footshock, and operant nose-poke and touch-screen reinforcement schedules.

Anxiety-related tests for rodents are primarily approach-avoidance conflicts. Mice are nocturnal. They prefer to be in dimly lit, enclosed environments. The current gold standard for anxiety-like tests for mice is the elevated plus-maze, which consists of two open and two enclosed arms, raised 1 meter from the floor, thus offering the choice between enclosed spaces and a high drop-off ledge. The corroborating light↔dark test consists of...
a two-compartment apparatus in which one chamber is dark and enclosed while the other chamber is open and brightly lit. Mice spend more time in the closed arms of the elevated plus-maze and more time in the dark compartment of the light ↔ dark apparatus. Excessive anxiety-like traits are interpreted when the preference is unusually high for the closed arms and for the dark compartment. Anxiolytic-like treatment responses are interpreted when mice venture out more frequently into the open arms of the elevated plus-maze and the brightly lit chamber of the light ↔ dark box.

Responses to sensory stimuli include acoustic startle, olfactory habituation and dishabituation to a series of non-social and social odors, and the hot plate and tail flick thermal tests. Hyperactivity is scored from automated parameters of locomotion in a series of non-social and social odors, and the hot plate and tail flick thermal tests. Hyperactivity is scored from automated parameters of locomotion in a novel open field. Unusual sleep patterns are scored by observations of the home cage during the daylight sleeping hours and during the nighttime active hours, and/or by EEG recordings.

Optimal animal models should incorporate: (i) face validity, i.e., close analogies to the defining features of the human syndrome; (ii) construct validity, i.e., the biological dysfunction that causes the human disease, such as a gene mutation or anatomical abnormality; and (iii) predictive validity, i.e., responsiveness to treatments that prevent or reverse symptoms in the human disease. The best animal models of autism and related developmental disorders will maximize face, construct, and predictive validities. At present this combination represents a very small subset of the model systems in use, particularly for neurodevelopmental disorders in which no effective therapeutics exist to test predictive validity of the animal model. The selected examples below are designed to illustrate the progress and promise of the mouse modeling approach in autism basic research and therapeutic development.

Our goal is to systematically analyze the wealth of emerging animal models of neurodevelopmental disorders, understand the strengths and weaknesses of each, gain basic knowledge about phenotypic outcomes, and employ the best model systems for treatment discovery.

How do we discover therapeutics using mouse models?

The unmet medical need for effective treatments for neurodevelopmental disorders is striking. The number of reported cases of autism has risen rapidly over the past decade. This rapid rise is largely a function of better diagnostic instruments and public awareness, although possible environmental causes and gene × environment interactions are under investigation. 
Personal and financial costs are high, to the affected individuals, their families, schools, and health care providers. At present the only effective interventions are intensive behavioral therapies.\textsuperscript{29,43} The only pharmacological treatments approved by the US Food and Drug Administration are risperidone and aripiprazole: Risperdol\textsuperscript{TM} and Abilify.\textsuperscript{TM} Their approved use is solely for the associated “irritability,” which includes aggression, self-injury, and tantrums.\textsuperscript{95}

A major revelation from the genetic association studies is that the most frequent mutations in autism are in genes that mediate the formation and maturation of synapses, particularly the postsynaptic densities, dendritic spines, and signaling mechanisms downstream from receptors mediating excitatory neurotransmission.\textsuperscript{96-100} Pharmacological agents that alter synaptic functions are already available to some extent, and next-generation compounds are under development.\textsuperscript{101-104} To evaluate the ability of novel drug treatments to reverse and/or prevent the symptoms of diseases, biomedical researchers often begin by testing exploratory compounds in appropriate animal models. Robust behavioral phenotypes with face validity to autism, in mouse models with construct validity to autism spectrum disorders, hold great promise for preclinical tools for discovering effective treatments for components of autism spectrum disorders.

Because rodents are similar to humans in many aspects of biochemistry, physiology, anatomy, and genetics, mice and rats are routinely employed in biomedical research as translational systems. Compounds that reverse behavioral and biological phenotypes in mouse models of autism offer leads which may be worth pursuing in human clinical trials. However, species differences exist in drug metabolism, alternate biochemical pathways, genetic variants, and toxicity. As in any field of biomedical research employing model systems, 100% predictive validity of efficacy and practicality in humans cannot be expected.

Keeping these caveats in mind, we design rigorous methods to evaluate proposed therapeutic interventions for autism spectrum disorders for their ability to reverse and/or prevent the major phenotypes in mouse models.\textsuperscript{29,43} Behavioral pharmacologists test acute and chronic drug treatments, across a dose range, at various time points after administration, and assay for the most robust autism-relevant behaviors, in the strongest mouse models. Examples of some of the successes are described in the next section.

**Mouse models with high translational value**

**Cell surface adhesion glycoproteins**

Cell surface adhesion glycoproteins are a primary mechanism through which connections of presynaptic axons and postsynaptic dendrites are elaborated in neuronal synapses.\textsuperscript{97,109} Mutations in cell surface protein genes have been reported with comparatively high frequency in neurodevelopmental disorders. Individuals with autism have been identified with mutations in NEUREXIN1, NEUROLIGIN3, NEUROLIGIN4, SHANK2, SHANK3, and CNTNAP2. For each of these rare mutations, a small number of individuals with the mutations who meet the diagnostic criteria for autism spectrum disorder has been identified.\textsuperscript{96-105} Mice with homologous mutations in these genes are available from several excellent molecular genetics laboratories and from The Jackson Laboratory repository.

**Shank3 knockout mice**

Shank3 knockout mice present a particularly fascinating example of the importance of the location of the mutation within the gene. The Shank3 gene includes an ankyrin repeat domain, a PDZ domain, and a Homer binding domain.\textsuperscript{103,107} Five distinct lines of Shank3 knockout mice with mutations at these various sites were generated and phenotyped in the past 2 years.\textsuperscript{71,103,113,114} Two lines of Shank3 knockouts containing the mutation at the ankyrin domain displayed impairments in excitatory neurotransmission and long-term potentiation, but were predominantly normal on standard measures of sociability, with only small genotype differences detected in ultrasonic vocalizations and repetitive behavior.\textsuperscript{71,81} Inserting the mutation at the Homer binding site resulted in mice with more social interactions, primarily in the form of aggression, along with mostly normal dendritic spines, reduced long-term potentiation, and enhanced long-term depression.\textsuperscript{113} When the mutation was in the PDZ domain, Shank3 knockouts displayed much more severe phenotypes, including high spontaneous self-grooming resulting in skin lesions, impaired sociability, reduced corticostriatal excitatory transmission, longer dendritic spines, and lower density of dendritic spines, as compared with wild-type controls.\textsuperscript{81} These divergent outcomes of mutations at differing sites within the same gene provide a unique opportunity to
Clinical research

understand the binding partners and their downstream signaling actions that determine the severity of symptoms in humans. For example, deficits in mGluR5 signaling have been reported after Shank3 knockdown in neuronal cultures.\footnote{115} Augmentation of mGluR5 activity could be beneficial in cases of autism with Shank3 mutations, and in individuals with Phelan-McDermid syndrome, an intellectual disability syndrome in which the Shank3 mutation is central to the 22q13 chromosomal deletion.\footnote{108}

**Contactin associated protein 2 (Cntnap2)**

Contactin associated protein 2 (Cntnap2), a member of the neurexin superfamily, plays a role in neuron-glia interactions and neuronal migration during early brain maturation. Mutations in CNTNAP2 are associated with autism in a small number of individuals, particularly with language disabilities.\footnote{107} Cntnap2 knockout mice were generated to understand the actions of this protein on brain development and autism-relevant behaviors.\footnote{40} Seizures were detected in 9 out of 10 null mutants. Social behaviors were impaired on the 3-chambered task, during reciprocal interactions, and in home cage nesting. Repetitive self-grooming was elevated. Resistance to change was seen in the Morris water maze, in which the initial learning was normal but the Cntnap2 knockouts failed the reversal test when the escape platform location was changed. Less spontaneous alternation in a T-maze was seen in the null mutants, concomitant with moderate hyperactivity. Reduced number of GABAergic interneurons and impaired migration of cortical projection neurons in this line of Cntnap2 mice underlie their seizures and some of their behavioral abnormalities. The Geschwind team proceeded to test risperidone, the antipsychotic approved by the US Food and Drug Administration for the treatment of irritability in autism. At 0.2 mg/kg IP daily for 7 days, a dose and regimen which did not affect locomotion in the wildtype controls, risperidone reduced the hyperactivity and repetitive self-grooming in Cntnap2 null mutant mice.\footnote{40} Social behaviors were unaffected by the treatment with risperidone, which is an atypical antipsychotic.

Single gene mutations, chromosomal deletions, and duplications cause a variety of neurodevelopmental disorders, including Fragile X, Rett, Angelman, Prader-Willi, Smith-Lemli-Opitz, Timothy, Williams, and Phelan-McDermid syndromes, and tuberous sclerosis.\footnote{115,116} A surprisingly large number of these de novo mutations code for signaling proteins that mediate the biochemical events downstream to postsynaptic neurotransmitter receptors. Interactome network analyses revealed convergences in genes that mediate transcriptional and splicing mechanisms that may be dysregulated in autism spectrum disorders.\footnote{115} Mutant mouse models of many of these syndromes have been generated.\footnote{115,116,117} While clinically distinct disorders caused by known single gene mutations suggest straightforward targets, as compared with complex disorders such as cases of autism in which the genetic substrates are unknown, increasing knowledge about the actions of downstream signaling proteins could identify pharmacological interventions which target key mechanistic sites in convergent biochemical cascades. Mice with homologous mutations are being employed as translational tools to evaluate convergent downstream target mechanisms, and to screen compounds that yield useful interventions at those sites.

**Tuberous sclerosis**

Tuberous sclerosis, caused by a mutation in the Tsc1 or Tsc2 gene, is characterized by benign tubers in the cerebral cortex, seizures, a high incidence of intellectual impairment, and frequent comorbidity with autism.\footnote{123} Tsc1 and Tsc2, which dimerize, are downstream targets of the PI3K/Akt postsynaptic signaling pathway elements that bind to mTORC2, and regulate mTORC1 at a further downstream site.\footnote{117} mTOR, the mammalian target of rapamycin, is a serine/threonine kinase which regulates many facets of brain development and cytoskeletal organization.\footnote{116} Deletion of Tsc1 in knockout mice, hippocampal slices, or cortical cultures resulted in enlarged brains, large dysmorphic astrocytes, decreased myelination, reductions in γ-aminobutyric acid (GABA)-ergic interneurons in the cerebral cortex, and loss of mGluR-dependent long-term depression.\footnote{126} Mice with mutations in Tsc2 display neuronal hypertrophy, reduced long-term potentiation in hippocampal slices, impaired hippocampally mediated fear conditioning, and impaired water maze learning.\footnote{126} Treatment with the mTOR inhibitor rapamycin for 5 days reversed the fear conditioning deficit and improved water maze learning, along with reducing brain weight and increasing survival.\footnote{126} This early demonstration of a pharmacological rescue of phenotypes in a mouse model of a neurodevelopmental
disorder sparked optimism for treating disorders caused by perturbations in signal transduction. In a separate mutant line, 4 weeks of treatment with rapamycin reduced the macroencephaly and increased the low social interaction in mice with a mutation in Pten, an upstream regulator of mTOR that is implicated in cancers, seizures, and autism. Rapalogs, analogs of mTOR, are in clinical trials for cancers, and in clinical trials for cancers, are in clinical trials for cancers, are in clinical trials for cancers. Rapalogs and compounds targeting PI3K and Akt present possibilities for therapeutic interventions in neurodevelopmental disorders with underlying mechanisms in the mTOR signaling pathway.

**Fragile X syndrome**

Fragile X syndrome is the most frequent genetic cause of intellectual disabilities. Constriction at the end of the X chromosome, termed a fragile site, is associated with a dramatic expansion of CGG triplet repeats, which transcriptionally silence the *FMR1* gene. Fragile X mental retardation protein (FMRP) is highly expressed in the brain, where it negatively regulates the synthesis of a large number of downstream proteins. Mice with a mutation in *Fmr1* display impairments in long-term potentiation, unusual social behaviors, and some unusual cognitive and anxiety-related behaviors.

One functional consequence of the *FMR1* mutation is upregulation of mGluR5 receptors. Bear and colleagues discovered that crossing *mGluR5* knockout mice with *Fmr1* knockout mice rescued the impaired long-term depression, elevated the dendritic spine densities in the hippocampus, and attenuated seizures. Negative allosteric modulators of the mGluR5 receptor were therefore postulated as potential treatments for Fragile X Syndrome. Clinical trials are in progress to test this hypothesis. Approximately 30% of individuals with Fragile X syndrome meet the diagnostic criteria for autism. Considering this high comorbidity, we reasoned that a treatment effective in Fragile X Syndrome might act through a pathway convergent with other risk genes for autism. We discovered that the prototypic mGluR5 antagonist 6-methyl-2-(phenylethyl) pyridine (MPEP), and GRN-529, a more selective negative allosteric modulators of the mGluR5 receptor, reduced the high levels of repetitive self-grooming in BTBR mice, an inbred strain that displays robust social deficits, low vocalizations in social settings, and high repetitive self-grooming and digging. Further, MPEP reduced marble burying in *Fmr1* knockout mice, reduced stereotypies in Swiss-Webster mice, and reduced repetitive self-grooming and marble burying in mice pretreated prenatally with valproic acid. These reports lend credence to the notion that interventions acting through mGluR5 receptors could confer specific benefits for treating repetitive behaviors, a major component of the third diagnostic symptom of autism.

**Conclusions**

Promising early findings of therapeutic rescues in mouse models have energized the rational search for pharmacoLOGICAL treatments of autism spectrum disorder. While the optimal developmental period for pharmacological intervention remains to be determined, adults with autism will likely be recruited for the first clinical trials, since the risks of adverse drug reactions are predicted to be greater in children. Challenges will include discovering the critical window during development and/or adulthood at which interventions are useful, dosages, and treatment regimens which minimize toxicity. We have taken the first step in a long journey.

**Acknowledgements:** We thank Dr Mu Yang for Figures 1a and 3a, and Dr Jennifer Brielmaier for Figure 1b. Dr Yang was a Research Fellow and Dr Brielmaier was a Postdoctoral Fellow in the author’s Laboratory of Behavioral Neuroscience, National Institute of Mental Health Intramural Research Program, Bethesda, MD.

**REFERENCES**

1. Kanner L. Child psychiatry; mental deficiency. *Am J Psychiatry.* 1946;102:520-522.
2. Asperger H. Die “Autistischen Psychopathen” im kindesalter. *Archiv fur Psychiatrie und Nervenkrankheiten.* 1944;117:76-136.
3. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders.* 4th ed. Washington, DC: American Psychiatric Association; 1984.
4. El-Fishawy P, State MW. The genetics of autism: key issues, recent findings, and clinical implications. *Psychiatr Clin North Am.* 2010;33:83-105.
5. Cook EH, Jr, Scherer SW. Copy-number variations associated with neuropsychiatric conditions. *Nature.* 2008;455:919-923.
6. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. *Science.* 2007;316:445-449.
7. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron.* 2011;70:863-885.
Clinical research

Modelos animales traslacionales de autismo y trastornos del neurodesarrollo

El autismo es un trastorno del neurodesarrollo cuyo diagnóstico se basa en tres criterios conductuales: interacciones sociales recíprocas inusuales, déficit en la comunicación y conductas repetitivas estereotipadas con intereses disminuidos. Los trastornos del espectro autista están asociados con un gran número de mutaciones monogénicas de novo y delecciones cromosómicas. En base a la gran evidencia genética, se han generado ratones con mutaciones específicas en genes homólogos como herramientas de investigación traslacional. Hay modelos de autismo en el ratón que han revelado resultados conductuales y biológicos que corresponden a mutaciones en genes de riesgo en genes de riesgo. Este campo ahora está preparado para emplear las fenotipos más potentes en los modelos de ratón más reproducibles para la evaluación preclínica de nuevas terapéuticas.

Modèles animaux translationnels des troubles autistiques et neurodéveloppementaux

L’autisme est un trouble du neurodéveloppement dont le diagnostic se fonde sur 3 critères comportementaux : des interactions sociales réciproques inhabituelles, des déficits de communication et des comportements répétitifs stéréotypés accompagnés d’intérêts restreints. Les troubles autistiques sont associés à de nombreuses mutations monogéniques de novo et à des délétions chromosomiques. Sur la base des arguments génétiques solides, des souris aux mutations ciblées sur des gènes homologues ont été élevées comme outil de recherche translationnelle. Les modèles murins d’autisme ont présenté des mutations biologiques et comportementales correspondant aux mutations des gènes à risque. Ce domaine de recherche est maintenant prêt à employer les phénomènes les plus fiables des modèles murins les plus reproducibles pour le dépistage préclinique de nouveaux traitements.

8. Levy D, Ronemus M, Yamrom B, et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. *Neuron*. 2011;70:886-897.
9. Girirajan S, Brkanac Z, Coo BP, et al. Relative burden of large CNVs on a range of neurodevelopmental phenotypes. *PLoS Genet*. 2011;7:e1002334.
10. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, Weinstein EJ. Targeted integration in rat and mouse embryos with zinc-finger nucleases. *Nat Biotechnol*. 2011;29:64-67.
11. Bauman MD, Toscano JE, Babinneau BA, Mason WA, Amaral DG. Emergence of stereotypes in juvenile monkeys (Macaca mulatta) with neonatal amygdala or hippocampus lesions. *Behav Neurosci*. 2008;122:1005-1015.
12. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. *J Neurosci*. 2007;27:10695-10702.
13. Heo Y, Zhang Y, Gao D, Miller VM, Lawrence DA. Aberrant innate responses in a mouse with behavioral disorders. *PLoS One*. 2011;6:e26077.
14. Mehta MV, Gandal MJ, Siegel SJ. mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. *PLoS One*. 2011;6:e20912.
15. Berman RF, Pessah IN, Mouton PR, Mav D, Harry J. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. *Toxicol Sci*. 2008;101:294-309.
16. Bauman MD, Lavener P, Mason WA, Capitanio JP, Amaral DG. The development of social behavior following neonatal amygdala lesions in rhesus monkeys. *J Cogn Neurosci*. 2004;16:1388-1411.
17. Martin LA, Ashwood P, Braunschweig D, Cabanilt M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. *Brain Behav Immun*. 2008;22:806-816.
18. Malkova L, Mishkin M, Suomi SJ, Bachevalier J. Long-term effects of neonatal medial temporal ablations on socioemotional behavior in monkeys (Macaca mulatta). *Behav Neurosci*. 2010;124:742-760.
19. Lord C, Petkova E, Hus V, et al. A multisite study of the clinical diagnosis of different autism spectrum disorders. *Arch Gen Psychiatry*. 2012;69:306-313.
20. Lord C, Cook EH, Leventhal BL, Amaral DG. Autism spectrum disorders. *Neuron*. 2000;28:355-363.
21. Tuchman R, Moshe SL, Rapin I. Convulsing toward the pathophysiology of autism. *Brain Dev*. 2009;31:95-103.
22. Rogers SJ, Ozonoff S. Annotation: what do we know about sensory dys-function in autism? A critical review of the empirical evidence. *J Child Psychol Psychiatry*. 2005;46:1255-1268.
23. Landi R. Diagnosis of autism spectrum disorders in the first 3 years of life. *Nat Clin Pract Neurol*. 2008;4:138-147.
24. Volkoff, State M, Klin A. Autism and autism spectrum disorders: diagnostic issues for the coming decade. *J Child Psychol Psychiatry*. 2009;50:108-115.
25. Amaral D, Dawson G, Geschwind, DH. Autism Spectrum Disorders. New York, NY: Oxford University Press; 2011.
26. Dawson G, Burner K. Behavioral interventions in children and adolescents with autism spectrum disorder: a review of recent findings. *Curr Opin Pediatr*. 2011;23:616-620.
27. Nakatani J, Tamada K, Hatanaka F, et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. *Cell*. 2009;137:1235-1246.
28. Yang M, Silverman JL, Crawley JN. Automated three-chambered social approach task for mice. *Curr Protoc Neurosci*. 2011;Chapter 8:Unit 8.26.
29. Crawley JN. Designing mouse behavioral tasks relevant to autistic-like behaviors. *Ment Retard Dev Disabil Res Rev*. 2004;10:248-258.
30. Nadler JJ, Moy SS, Dold G, et al. Automated apparatus for quantitation of social approach behaviors in mice. *Genes Brain Behav*. 2004;3:303-314.
31. Brodkin ES. BALB/c mice: low sociability and other phenotypes that be relevant to autism. *Behav Brain Res*. 2007;176:53-65.
32. DeLorey TM, Sabaiea P, Hashemi E, Homanics GE, Clark JD. Gabrel3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. *Behav Brain Res*. 2008;187:207-220.
33. Ryan BC, Young NB, Moy SS, Crawley JN. Ofactory cues are sufficient to elicit social approach behaviors but not social transmission of food preference in C57Bl/6J mice. *Behav Brain Res*. 2008;193:235-242.
34. Page DT, Kuti OJ, Prestica C, Sur M. Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior. Proc Natl Acad Sci U S A. 2009;106:1989-1994.
35. Radysuzhikin K, Hammerschmidt K, Boretius S, et al. Neuroglin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 2009;8:416-425.
36. Yang M, Crawley JN. Simple behavioral assessment of mouse olfaction. Curr Protoc Neurosci. 2009;Chapter 8:Unit 8.24.
37. Silva AJ, Ehringer D. Adult reversal of cognitive phenotypes in neurodevelopmental disorders. J Neurodev Disord. 2009;1:150-157.
38. Zhou J, Blundell J, Ogawa S, et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci. 2009;29:1773-1783.
39. Etherton M, Foulds C, Sharma M, et al. Autism-linked neuroglin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A. 2011;10:18:13764-13769.
40. Penagarikano O, Abrahms BS, Herman EI, et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011;147:235-246.
41. Silverman J, Turner S, Barkan C, et al. Sociability and motor functions in Shank1 mutant mice. Brain Res. 2011;1380:120-137.
42. Polbee RL, Pearson BS, Defensor ER, Bolivar VJ, Blanchard DC, Blanchard RJ. Expression of social behaviors of C57BL/6J versus BTBR inbred mouse strains in the visible burrow system. Behav Brain Res. 2010;214:443-449.
43. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010;11:490-502.
44. Smith SE, Zhou YD, Zhang G, Jin Z, Stoppel DC, Anderson MP. Increased olfactory deficit. Proc Natl Acad Sci U S A. 2011;108:13764-13769.
45. Crawley JN. What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc; 2007.
46. Grant E, Machtosh J. A comparison of the social postures of some common laboratory rodents. Behaviour. 1963;21:246-259.
47. Carter CS, Williams JR, Witt DM, Insel TR. Oxytocin and social bonding. Ann N Y Acad Sci. 1992;652:204-211.
48. Terranova ML, Laviola G. Scoring of Social Interactions and Play in Mice During Adolescence. Vol 13. Hoboken, NJ: John Wiley & Sons, Inc; 2005.
49. Hofer MA, Shair HN. Ultrasonic vocalization, laryngeal braking, and thermogenesis in rat pups: a reappraisal. Behav Neural. 1993;107:354-362.
50. Mizcek KA, Maxson SC, Fish EW, Faccidomo S. Aggressive behavioral phenotypes in mice. Behav Brain Res. 2001;125:167-181.
51. Wesson DW, Keller M, Douhard Q, Baum MJ, Bakker J. Enhanced urinary odor discrimination in female aromatase knockout (ArKO) mice. Mol Genet Metab. 2007;91:145-163.
52. Yang M, Zhodzishvky S, Crawley JN. Social deficits in BTBR T+tf/J mice are unchanged by cross-fostering with C57BL/6J mothers. Int J Dev Neurosci. 2007;25:515-521.
53. Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol. 2007;17:448-459.
54. Crawley JN, Chen T, Puru A, et al. Social approach behaviors in oxytocin knockout mouse: comparison of two independent lines tested in different laboratory environments. Neuropeptides. 2007;41:145-163.
55. Yang M, Scattoni ML, Zhodzishvky V, et al. Social approach behaviors are similar on conventional versus reverse lighting cycles, and in replications across cohorts, in BTBR T+tf/J, C57BL/6J, and vasopressin receptor 18 mutant mice. Front Behav Neurosci. 2007;11:1.
56. Chadman KK, Gong S, Scattoni ML, et al. Minimal aberrant behavioral phenotypes of neuroglin-3 R451C knockin mice. Autism Res. 2008;1:147-158.
57. Jamain S, Radysuzhikin K, Hammerschmidt K, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci U S A. 2008;105:1710-1715.
58. Pozzoboni O, Sakurai T, Papapetrou D, et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism. 2010;1:15.
59. Holy TE, Guo Z. Ultrasonic songs of male mice. PLoS Biol. 2005;3:e386.
60. Yang M, Scheck AK, Yang SB, YN, LY. Altered ultrasonic vocalizations in a transgenic mouse model of autism. J Neurosci. 2011;31:109:145-163.
Clinical research

85. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005;4:775-790.
86. Fox W. Reflex-ontogeny and behavioural development of the mouse. Animal Behavior. 1969;13:234-241.
87. Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev. Spring 1985;9:37-44.
88. Crawley J, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav. 1980;13:167-170.
89. Rice C, et al. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009;58:1-20.
90. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65:591-598.
91. Charman T, Pickles A, Chandler S, et al. Commentary: Effects of diagnostic thresholds and research vs service and administrative diagnosis on autism prevalence. Int J Epidemiol. 2009;38:1234-1238; author reply 1234-1234.
92. Rice C, Nicholas J, Baio J, et al. Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disabil Health J. 2010;3:186-201.
93. Durkin MS, Maenner MJ, Meaney FJ, et al. Socioeconomic inequality in the prevalence of autism spectrum disorder: evidence from a U.S. cross-sectional study. PLoS One. 2010;5:e11551.
94. Zwaigenbaum L, Bryson S, Lord C, et al. Clinical assessment and management of toddlers with suspected autism spectrum disorder: insights from studies of high-risk infants. Pediatrics. 2009;123:1383-1391.
95. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol. 2010;12:529-538.
96. Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol. 2009;19:231-234.
97. Betancur C, Sakurati T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 2009;32:402-412.
98. Buxbaum JD. Multiple rare variants in the etiology of autism spectrum disorders. Dialogues Clin Neurosci. 2009;11:35-43.
99. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Rev Neurosci. 2011;14:285-293.
100. Hutslar JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 2010;1309:83-94.
101. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W. The effect and cognition: a comparison. Psychopharmacology (Berl). 2005;179:218-229.
102. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics. 2010;7:264-274.
103. Lynch G, Palmer LC, Gail CM. The likelihood of cognitive enhancement. Pharmacol Biochem Behav. 2011;99:116-129.
104. Brennand KJ, Gage FH. Concise review: therapeutic insights from studies of schizophrenia. Stem Cells. 2011;29:1915-1922.
105. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455:903-911.
106. Casey JP, Magalhaes T, Conroy JM, et al. A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet. 2012;131:565-579.
107. Alarcon M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNNTAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008;82:150-159.
108. Sarasua SM, Dvivedi A, Boccuto L, et al. Association between deletion size and important phenotypes expands the genomic region of interest in Phelan-McDermid syndrome (22q13 deletion syndrome). J Med Genet. 2011;48:761-766.
109. Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34:27-29.
110. Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y. SAPAP3. A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J Biol Chem. 1997;272:11943-11951.
111. Sheng M, Kim E. The Shank family of scaffold proteins. J Cell Sci. 2000;113(Pt 11):1851-1856.
112. Hayashi MK, Tang C, Verpelli C, et al. The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell. 2009;137:159-171.
113. Bangash MA, Park JM, Melnikova T, et al. Enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell. 2011;145:758-772.
114. Wang X, McCoy PA, Rodriguiz RM, et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 2011;20:3093-3108.
115. Verpelli C, Durovetskova E, Vicidomini C, et al. Importance of shank3 in regulating metabotropic glutamate receptor 5 (mGlur5) expression and signaling at synapses. J Biol Chem. 2011;286:34839-34850.
116. Whalley HC, O’Connell G, Susams J, et al. Genetic variation in CNTNAP2 alters brain function during linguistic processing in healthy individuals. Am J Med Genet B Neuropsychiatr Genet. 2011;156B:941-948.
117. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474:380-384.
118. Hayashi ML, Rao BS, Seo JS, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 2007;104:11489-11494.
119. Zoghbi HY. Rett syndrome: what do we know for sure? Nat Neurosci. 2009;12:239-240.
120. Moretti P, Bourkneche JA, Teague R, Paylor R, Zoghbi HY. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet. 2005;14:205-220.
121. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampican treatment in a mouse model of Rett syndrome. J Neurosci. 2007;27:10912-10917.
122. Lauterborn JC, Rex CS, Krae, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci. 2007;27:10685-10694.
123. Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J Child Neurol. 2008;23:268-273.
124. Cuasmat R, Molareo R, Bombardiere R, Vigevano F, Curatolo P. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav. 2011;22:735-739.
125. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37(Pt 1):217-222.
126. Carson RP, Van Nielen DL, Winzenburger PA, Ess KC. Neuronal and glial abnormalities and gli abnormalities in Tsc1-deficient forebrain and partial seizure by rapamycin. Neurobiol Dis. 2012;45:369-380.
127. Khwaja OS, Sahin M. Translational research: Rett syndrome and tuberous sclerosis complex. Curr Opin Pediatr. 2011;23:633-639.
128. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008;14:843-848.
129. Ehninger D, Li W, Fox K, Stryker MR, Silva AJ. Reversing neurodevelopmental disorders in adults. Neuro. 2008;60:950-960.
130. Schatz JH. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin’s lymphoma: results, biology, and development strategies. Curr Oncol Rep. 2011;13:398-406.
131. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol. 2011;6:103-117.
132. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of the CGI repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell. 1991;67:1047-1058.
133. Pieretti M, Zhang FR, Fu YH, et al. Absence of expression of the FMR1 gene in fragile X syndrome. Cell. 1991;66:817-822.
134. Dobrov V, Jin P, Cerman S, et al. Mutations in FMR1 associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107:477-487.
135. Gantios I, Bakker CE, Reynolds E, et al. Restoring the phenotype of fragile X syndrome: insight from the mouse model. Curr Med Chem. 2001;8:447-455.
136. Mineur YS, Huynh LX, Crisolo WE. Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res. 2006;168:172-175.
137. Chen LY, Rex CS, Babayan AH, et al. Physiological activation of synaptic Racc/PK (p-21 activated kinase) is defective in a mouse model of fragile X syndrome. J Neurosci. 2010;30:10977-10984.
138. Spencer CM, Graham DF, Yuva-Paylor LA, Nelson DL, Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci. 2008;122:710-715.
139. Baker KB, Wray SP, Ritter R, Mason S, Lanthorn TH, Savelieva KV. Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes Brain Behav. 2010;9:562-574.
140. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99:7746-7750.
141. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56:955-962.
142. Krueger OD, Bear MF. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med. 2011;62:411-429.
143. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: intertwoven at the molecular level leading to targeted treatments. Mol Autism. 2010;1:12.
144. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480:63-68.
145. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile x syndrome and targeted treatment trials. Results Probl Cell Differ. 2012;54:297-335.
146. Silverman JL, Smith DG, Rizzo SJ, et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med. 2012;4:131ra51.
147. Bolivar VJ, Walters SR, Phoenix JL. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res. 2007;176:21-26.
148. Pearson BL, Pobbe RL, Defensor EB, et al. Motor and cognitive stereotypies in the BTBR T+tf/J mouse model of autism. Genes Brain Behav. 2011;10:44-56.
149. Scattoni ML, Gandhy SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. Genes Brain Behav. 2011;10:35-43.
150. Carter MD, Shah CR, Muller CL, Crawley JN, Carneiro AM, Veenstra-Vanderweele J. Absence of preference for social novelty and increased grooming in integrin beta2 knockout mice: initial studies and future directions. Autism Res. 2011;4:57-67.
151. Blundell J, Blaiss CA, Etherton MR, et al. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J Neurosci. 2010;30:2115-2129.
152. Radyushkin K, Hammerschmidt K, Boretti S, et al. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 2009;8:416-425.
153. Janma S, Radyushkin K, Hammerschmidt K, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci U S A. 2008;105:1710-1715.
154. Scattoni ML, Gandhy SU, Ricceri L, Crawley JN. Unusual repertoire of vocalizations in the BTBR T+tf/J mouse model of autism. PLoS One. 2008;3:e3067.
155. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci. 2010;11:490-502.
156. Blundell J, Tabuchi K, Bolliger MF, et al. Increased anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion molecule neuroligin 2. Genes Brain Behav. 2009;8:114-126.
157. Martini GJ, Plachez C, Powell EM. Loss of embryonic MET signaling alters profiles of hippocampal interneurons. Dev Neurosci. 2007;29:143-158.
158. Shu W, Cho JY, Jiang Y, et al. Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. Proc Natl Acad Sci U S A. 2005;102:9643-9648.
159. Fujita E, Tanabe Y, Shiota A, et al. Ultrasonic vocalization impairment of Foxp2 (R552H) knockin mice related to speech-language disorder and abnormality of Purkinje cells. Proc Natl Acad Sci U S A. 2008;105:3117-3122.
160. Enard W, Gehre S, Hammerschmidt K, et al. A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. Cell. 2009;137:961-971.
161. Blaiss CA, Etherton MR, Le V, Young LJ. Profound impairment in social recognition and reduction in anxiety-like behavior in vasoressin V1a receptor knockout mice. Neuropsychopharmacology. 2004;29:483-493.
162. Martini GJ, Plachez C, Powell EM. Loss of embryonic MET signaling alters profiles of hippocampal interneurons. Dev Neurosci. 2007;29:143-158.
163. Pobbe RL, Pearson BL, Defensor EB, et al. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm Behav. In press.
164. Sala M, Braida D, Lentinli D, et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry. 2011;69:875-882.
165. Macbeth AH, Stepe EJ, Lee HJ, Young WS, 3rd, Caldwell HK. Normal maternal behavior, but increased pup mortality, in conditional oxytocin receptor knockout females. Behav Neurosci. 2010;124:677-685.
166. Brielmaier J, Matteson PG, Silverman JL, et al. Autism-relevant social abnormalities and cognitive deficits in engrafted 2 knockout mice. PLoS One. 2012;7:e40914.